CORZQ — Core Scientific Income Statement
0.000.00%
Last trade - 00:00- $536.57m
- $1.36bn
- $640.31m
- 18
- 30
- 89
- 43
Annual income statement for Core Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 59.5 | 60.3 | 544 | 640 |
| Cost of Revenue | ||||
| Gross Profit | 10.5 | 9.39 | 239 | 8.4 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 71.2 | 68 | 421 | 2,553 |
| Operating Profit | -11.7 | -7.66 | 123 | -1,912 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -11.9 | -12.2 | 63.1 | -2,163 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -11.9 | -12.2 | 47.3 | -2,146 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -11.9 | -12.2 | 47.3 | -2,146 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -11.9 | -22.7 | 47.3 | -2,146 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.04 | -0.086 | 0.251 | -3.09 |
| Dividends per Share |